Masato Fujii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masato Fujii has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Yutaka Tokumaru
10 shared publications- Noboru Habu
Department of Otorhinolaryngology, Kyosai Tachikawa Hospital, Tachikawa, Tokyo, 190-0022, Japan
6 shared publications Yoko Yajima
4 shared publications- Koichi Tsunoda
Department of Artificial Organs, National Institute of Sensory Organs, Tokyo, Japan
3 shared publications Akihito Shindo
2 shared publicationsJin Kanzaki
2 shared publications
Latest Publications
- 1 January 2014
- Published by The Society of Practical Otolaryngology in Practica oto-rhino-laryngologica. Suppl.
- Vol. 138, 132-133
A Case of Complex Regional Pain Syndrome after Tongue Cancer Operation
- 1 January 2014
- Published by The Society of Practical Otolaryngology in Practica oto-rhino-laryngologica. Suppl.
- Vol. 138, 132-133
A Case of Complex Regional Pain Syndrome after Tongue Cancer Operation
- 1 January 2013
- Published by The Society of Practical Otolaryngology in Practica Oto-Rhino-Laryngologica
- Vol. 106 (9) , 847-851
A Case of Complex Regional Pain Syndrome after Tongue Cancer Operation
- 1 January 2013
- Published by The Society of Practical Otolaryngology in Practica Oto-Rhino-Laryngologica
- Vol. 106 (9) , 847-851
A Case of Complex Regional Pain Syndrome after Tongue Cancer Operation
- 1 December 2010
- Vol. 37 (13) , 2861-5
[Hyponatremia with cisplatin administration in head and neck cancer patients].
Hyponatremia is one of the most common electrolyte disorders encountered in clinical practice of medical anticancer treatment. Cisplatin (CDDP) is a well-known chemotherapeutic agent that associates with hyponatremia. We retrospectively studied clinical features of hyponatremia CDDP administration. The incidence of hyponatremia at the first administration was 64. 1%. The significant risk factors of hyponatremia are body weight less than 60 kg, creatinin clearance less than 60mL/min, and sodium depletion and intake loss due to treatment-induced anorexia, nausea, vomiting and diarrhea. The mechanism of hyponatremia induced by CDDP is thought to be mainly renal salt wasting, and sometimes the syndrome of inappropriate secretion of antidiuretic hormone(SIADH).
- 1 December 2010
- Vol. 37 (13) , 2861-5
[Hyponatremia with cisplatin administration in head and neck cancer patients].
Hyponatremia is one of the most common electrolyte disorders encountered in clinical practice of medical anticancer treatment. Cisplatin (CDDP) is a well-known chemotherapeutic agent that associates with hyponatremia. We retrospectively studied clinical features of hyponatremia CDDP administration. The incidence of hyponatremia at the first administration was 64. 1%. The significant risk factors of hyponatremia are body weight less than 60 kg, creatinin clearance less than 60mL/min, and sodium depletion and intake loss due to treatment-induced anorexia, nausea, vomiting and diarrhea. The mechanism of hyponatremia induced by CDDP is thought to be mainly renal salt wasting, and sometimes the syndrome of inappropriate secretion of antidiuretic hormone(SIADH).
- 1 June 2010
- Vol. 30 (6) , 2005-10
Identification of stem-like cells in head and neck cancer cell lines.
This study investigated the existence of stem-like cells in established head and neck squamous cell carcinoma (HNSCC) lines, HSC3 and HSC4. Flow cytometric analysis confirmed the presence of side population (SP) cells excluding Hoechst 33342 in HSC4 cells (0.37+/-0.06%) but not HSC3 cells in a reserpine-sensitive manner. After sorting, the SP cells generated both SP and main population (MP) cells in culture while MP cells generated MP cells only. Higher expression of stem cell markers was detected in SP than in MP cells. These results suggest that cancer stem-like cells exist in head and neck squamous cell carcinoma.
- 1 June 2010
- Vol. 30 (6) , 2005-10
Identification of stem-like cells in head and neck cancer cell lines.
This study investigated the existence of stem-like cells in established head and neck squamous cell carcinoma (HNSCC) lines, HSC3 and HSC4. Flow cytometric analysis confirmed the presence of side population (SP) cells excluding Hoechst 33342 in HSC4 cells (0.37+/-0.06%) but not HSC3 cells in a reserpine-sensitive manner. After sorting, the SP cells generated both SP and main population (MP) cells in culture while MP cells generated MP cells only. Higher expression of stem cell markers was detected in SP than in MP cells. These results suggest that cancer stem-like cells exist in head and neck squamous cell carcinoma.
- 1 September 2009
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 141 (3) , P147
SP177 – Chemoradiotherapy for carcinoma of the pharynx and larynx
- 1 September 2009
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 141 (3) , P147
SP177 – Chemoradiotherapy for carcinoma of the pharynx and larynx
- 1 January 2009
- Published by Japan Society for Head and Neck Cancer in Toukeibu Gan
- Vol. 35 (4) , 360-364
HPV infection in head and neck squamous cell carcinoma
- 1 January 2009
- Published by Japan Society for Head and Neck Cancer in Toukeibu Gan
- Vol. 35 (4) , 360-364
HPV infection in head and neck squamous cell carcinoma
- 1 January 2007
- Published by Japan Society for Head and Neck Cancer in Toukeibu Gan
- Vol. 33 (3) , 352-355
Salvage surgery-Radical neck dissection after chemoradiotherapy-
- 1 January 2007
- Published by Japan Society for Head and Neck Cancer in Toukeibu Gan
- Vol. 33 (3) , 352-355
Salvage surgery-Radical neck dissection after chemoradiotherapy-
- 1 January 2006
- Published by Japan Society for Head and Neck Cancer in Toukeibu Gan
- Vol. 32 (4) , 410-416
ABERRANT PROMOTER HYPERMETHYLATION OF CYCLIN A1 IN CANCER
- 1 January 2006
- Published by Japan Society for Head and Neck Cancer in Toukeibu Gan
- Vol. 32 (4) , 410-416
ABERRANT PROMOTER HYPERMETHYLATION OF CYCLIN A1 IN CANCER
- 1 April 2002
- Published by Elsevier in Auris Nasus Larynx
- Vol. 29 (2) , 175-181
Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma
- 1 April 2002
- Published by Elsevier in Auris Nasus Larynx
- Vol. 29 (2) , 175-181
Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma
- Open Access
- 1 October 2000
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 126 (10) , 1217-1223
Role of CD44 Variant Exon 6 in Invasion of Head and Neck Squamous Cell Carcinoma
GLYCOPROTEIN CD44 is a cell surface molecule that appears to be involved in cell-cell and cell-matrix interactions. It also appears to mediate several other functions, such as lymphocyte homing,1 T-cell activation,2 and tumor metastasis.2,3 The CD44 gene measures 50 to 60 kd, resides on chromosome 11p13, and is known to be composed of at least 20 exons. Ten of the exons are constitutively expressed on almost all cell types to produce a heavily glycosylated 85- to 90-kd isoform known as the CD44 standard form (CD44st). The remaining exons can be alternatively spliced to produce various isoforms,3-5 which are called CD44 variants (CD44v).
- 1 October 2000
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 126 (10) , 1217-1223
Open AccessRole of CD44 Variant Exon 6 in Invasion of Head and Neck Squamous Cell Carcinoma
GLYCOPROTEIN CD44 is a cell surface molecule that appears to be involved in cell-cell and cell-matrix interactions. It also appears to mediate several other functions, such as lymphocyte homing,1 T-cell activation,2 and tumor metastasis.2,3 The CD44 gene measures 50 to 60 kd, resides on chromosome 11p13, and is known to be composed of at least 20 exons. Ten of the exons are constitutively expressed on almost all cell types to produce a heavily glycosylated 85- to 90-kd isoform known as the CD44 standard form (CD44st). The remaining exons can be alternatively spliced to produce various isoforms,3-5 which are called CD44 variants (CD44v).